# Korvin Merrow World Spec v1

Date created: 2026-06-01

Status: CANDIDATE REVIEW

Purpose: first complete World Spec candidate for the Korvin Merrow world, built only from locked physician-approved architecture.

This document describes the canonical world context for future task construction. It does not create file inventory rows, synthetic chart files, task prompts, expected outputs, golden responses, grader guidance, AutoQC responses, or submission artifacts.

## Source Constraints

Use only locked and ratified materials:

- Approved Brainstorm.
- Locked World Spec Skeleton v1.
- Locked Identity Package v1.
- Ratified Governance Package v1.
- Locked Key Milestones Calendar Skeleton v1.
- Locked Baseline Anchor Package v1.
- Locked Clinical Story Timeline Package v1.
- Locked Task Architecture Package v1.
- Locked Medication Expansion Package v1.
- Locked Comorbidity Expansion Package v1.
- Locked Provider Roster Package v1.
- Locked Surgical History Package v1.
- Locked Daily Hospital Course Framework v1.
- Current clinical logic.

## 1. Clinical Scenario

### Big Picture Summary

Korvin Merrow is a synthetic 62-year-old man in a Typical Clinical World centered on acute hospital medicine, discharge planning, medication reconciliation, consultant synthesis, and transition-of-care reasoning. The world begins with emergency department evaluation after approximately 3 weeks of decline and follows a 6-day hospitalization ending at the world snapshot on HD6, 05/23/2026 at 18:00.

The initial hospital frame is suspected urinary-source sepsis with poor intake, dehydration risk, altered baseline mental status, functional decline, and AKI-on-CKD risk. Sepsis-oriented stabilization is clinically reasonable. The world becomes difficult because partial improvement does not make the patient safely solved: steroid source ambiguity, HF/AKI medication timing, functional decline, family concern, consultant disagreement, and discharge-source hierarchy all remain clinically relevant.

The design target is not a hidden rare diagnosis. The world tests whether a clinician can reassess an evolving patient after stabilization, reconcile changing documentation, preserve the distinction between people-conflicts and information-traps, and decide whether the discharge plan is safe in the real world.

### Patient Profile

| Field | Locked value |
| --- | --- |
| Patient name | Korvin Merrow |
| World Type | Typical Clinical World |
| DOB | 1964-02-18 |
| Age | 62 |
| MRN | KM-6427819 |
| Height | 178 cm (5'10") |
| Weight | 97 kg (214 lb) |
| BMI | 30.6 |
| Allergy / intolerance | Lisinopril (cough) |
| Code status | Full Code |

Korvin lives with family. Before the decline, he was independent with activities of daily living but slowed by chronic illness. He used a cane occasionally for longer distances or bad days. His baseline cognition was mild age-related forgetfulness only; he was normally oriented and able to participate in daily routines. He managed some medications himself with family oversight, but the regimen was complex enough that errors could plausibly emerge during illness.

Locked baseline comparator anchors include baseline creatinine 1.6-1.8 mg/dL, baseline eGFR approximately 40-50 mL/min/1.73 m2, baseline hemoglobin 10.5-11.5 g/dL, baseline A1c 7.6-8.2%, dry weight approximately 97 kg, baseline mobility without major assistance, baseline cognition as above, partial medication self-management with family support, and a home environment where family knows his usual function. These are baseline anchors only, not admission values or hospital-course trends.

### Comorbidity Profile

The locked baseline comorbidity architecture contains 14 conditions. These conditions create realistic hospital medicine complexity without adding a new dominant disease arc.

| # | Condition | Why it matters to the world |
| --- | --- | --- |
| 1 | Heart failure with reduced ejection fraction | Drives long-term cardioprotective therapy and Cardiology vs Nephrology medication-restart tension. |
| 2 | Coronary artery disease | Supports secondary prevention, cardiology involvement, and the risk of losing protective therapy during transition. |
| 3 | Hypertension | Fits CKD/CAD/HFrEF and supports hemodynamic tension when blood pressure is borderline. |
| 4 | Hyperlipidemia | Supports chronic CAD risk reduction and medication continuity reasoning. |
| 5 | Chronic kidney disease stage 3 | Makes AKI recovery, renal-sensitive medications, and nephrology involvement clinically meaningful. |
| 6 | Type 2 diabetes mellitus | Supports infection vulnerability, baseline A1c context, medication complexity, and neuropathy. |
| 7 | Diabetic peripheral neuropathy | Supports baseline mobility vulnerability and the multi-factorial near-fall model. |
| 8 | Obstructive sleep apnea | Adds realistic chronic functional reserve burden without explaining the acute presentation alone. |
| 9 | Polymyalgia rheumatica | Provides the chronic prednisone exposure and taper uncertainty substrate. |
| 10 | Anemia of CKD | Adds chronic fatigue/reduced-reserve context without becoming a new acute anemia arc. |
| 11 | Osteoporosis / osteopenia from chronic steroid exposure | Corroborates cumulative steroid exposure but does not prove current adrenal suppression. |
| 12 | Class I obesity by BMI | Fits OSA, cardiometabolic disease, mobility reserve, and discharge planning. |
| 13 | Chronic gastroesophageal reflux / acid-suppression indication | Supports secondary medication burden and chronic aspirin/steroid context. |
| 14 | Chronic constipation tendency | Supports real-world medication burden and discharge instruction complexity. |

The condition profile preserves mixed physiology: infection, volume status, CKD/HF interaction, steroid exposure, neuropathy, anemia, OSA, deconditioning, and medication complexity all matter, but none is intended to be the single explanation.

### Medication Architecture

The locked baseline medication architecture contains 20 medication items. This section names the medication architecture and its reasoning role only. It does not create final medication doses, frequencies, schedules, hospital orders, admission medication reconciliation, or discharge medication lists.

| Category | Medication architecture | Role in world |
| --- | --- | --- |
| CAD / cardiovascular prevention | Aspirin; atorvastatin; nitroglycerin rescue medication | Preserves chronic secondary-prevention stakes and discharge medication continuity. |
| HFrEF / cardiorenal therapy | Sacubitril/valsartan; carvedilol; furosemide; spironolactone; empagliflozin | Central to HF/AKI medication timing, hypotension risk, renal recovery, and cardioprotective restart reasoning. |
| CKD/anemia support | Ferrous sulfate | Adds chronic disease burden and bowel-regimen complexity. |
| Diabetes therapy | Metformin ER; insulin glargine | Supports renal/acute-illness medication safety and home medication-management risk. |
| Neuropathy / pain support | Gabapentin; acetaminophen | Supports functional and cognitive safety reasoning without making one medication the answer. |
| Steroid-related therapy | Prednisone | Central to PMR history, taper uncertainty, steroid source-of-truth reconstruction, and Endocrinology vs Primary Team friction. |
| GI / bowel regimen | Pantoprazole; polyethylene glycol; senna | Adds realistic supportive-medication burden and chronic-vs-carried-forward reconciliation risk. |
| Bone-health therapy | Alendronate; calcium carbonate / vitamin D combination; cholecalciferol | Supports chronic steroid-exposure realism and supplement/medication reconciliation complexity. |

Insulin lispro is not part of the locked baseline medication architecture. It is reserved only as a future inpatient-only candidate during later hospital-course or file construction if explicitly authorized.

The medication burden supports several reasoning demands: avoid copying old medication lists, avoid treating early acute-illness holds as permanent, avoid premature restart of renal/hemodynamic-risk medications, and avoid losing long-term HFrEF/CAD protective therapy.

### Surgical / Procedural History

The locked procedural history is deliberately quiet and background-level.

Confirmed procedural anchors:

- Remote percutaneous coronary intervention with coronary stent placement.
- Remote diagnostic sleep study confirming obstructive sleep apnea.

Excluded/noise-controlled procedures for v1:

- ICD / CRT / pacemaker.
- Coronary artery bypass grafting.
- Dialysis access creation or kidney procedure.
- Major orthopedic fracture repair or joint replacement.
- Limb amputation or major diabetic foot surgery.
- Temporal artery biopsy or rheumatologic diagnostic procedure.
- Screening colonoscopy for v1 purposes.

Remote PCI supports CAD history, aspirin/statin/nitroglycerin logic, and cardiology's concern about chronic protective therapy. The sleep study supports OSA as background chronic disease. Neither procedure explains the acute hospitalization, near-fall, altered mental status, steroid concern, AKI, or discharge risk by itself.

### Provider Architecture And Source Hierarchies

High-authority recurring roles:

| Role | Name / label | Authority or source contribution |
| --- | --- | --- |
| Attending hospitalist | Dr. Elian Vossmere | Owns inpatient synthesis, consultant integration, and discharge-readiness interpretation. |
| Cardiology attending | Dr. Maris Caldrane | Represents HFrEF/CAD protection and GDMT restart perspective. |
| Nephrology attending | Dr. Iven Solthar | Represents AKI-on-CKD recovery, renal safety, hypotension, and volume concerns. |
| Endocrinology attending | Dr. Nerea Veylorn | Represents steroid/adrenal risk interpretation and safe prednisone/taper planning. |
| Primary care physician | Dr. Talia Quenor | Provides longitudinal baseline, chronic disease, outpatient medication, and follow-up context. |
| Outpatient rheumatology attending | Dr. Soren Halvek | Highest-authority source for PMR and prednisone-taper history. |
| Family/caregiver | Mara Merrow | Provides baseline function, cognition, medication-management, and home safety observations. |

Service-role placeholders:

- Hospitalist resident / covering clinician.
- Bedside nursing team.
- Physical Therapy.
- Occupational Therapy.
- Case Management.
- Social Work.
- Pharmacy / medication reconciliation pharmacist.

Authority hierarchy:

1. Attending Hospitalist.
2. Consulting Attending Specialists.
3. PT/OT Functional Assessments.
4. Case Management / Social Work.
5. Family Reports.
6. Patient Recollection.

Master source-of-truth hierarchy for clinical facts:

1. Attending Documentation.
2. Verified Medication Reconciliation.
3. Pharmacy History.
4. Consultant Documentation.
5. Primary Care Documentation.
6. Family Report.
7. Patient Recollection.

Prednisone-specific source-of-truth hierarchy:

1. Rheumatology attending recommendation.
2. Verified medication reconciliation.
3. Pharmacy / refill history.
4. Family report.
5. Patient recollection.

Governance rule: hierarchy resolves factual and documentation conflicts; it does not erase consultant disagreement. Cardiology, nephrology, endocrinology, hospital medicine, PT/OT, family, case management, social work, and pharmacy evidence still require synthesis across timing, trends, patient status, and discharge safety.

## 2. Timeline And Hospital Course

### Key Milestones

| Anchor | Date / timestamp | Role |
| --- | --- | --- |
| Decline begins | 04/27/2026 | Approximately 3-week pre-admission decline begins. |
| Final pre-admission week begins | 05/11/2026 | Late decline window. |
| Day before presentation | 05/17/2026 | Final pre-admission day. |
| HD1 / admission | 05/18/2026 | ED presentation and inpatient admission. |
| HD2 | 05/19/2026 | Early inpatient reassessment and consultant involvement begins. |
| HD3 | 05/20/2026 | Functional/cognitive concerns become more visible. |
| HD4 | 05/21/2026 | Consultant tensions and steroid-history uncertainty become explicit. |
| HD5 | 05/22/2026 | Disposition questions become dominant. |
| HD6 / world close day | 05/23/2026 | Discharge-planning snapshot day. |
| World close | 05/23/2026 18:00 | Closed-world snapshot. No world-level file may occur after this timestamp without explicit reopening. |
| Discharge anchor | 05/24/2026 | Post-world discharge-facing anchor. |
| +7 anchor | 05/31/2026 | 7 days after discharge anchor, not 7 days after world close. |
| +30 anchor | 06/23/2026 | 30 days after discharge anchor, not 30 days after world close. |

### Pre-Admission Decline

Korvin's decline begins around 04/27/2026. Over approximately 3 weeks, he becomes less active, eats and drinks less, grows weaker, depends more on family, reports or displays possible urinary symptoms, becomes progressively unsteady, shows cognitive slowing compared with baseline, and makes medication-management mistakes. The near-fall and lightheadedness are intentionally multi-factorial: poor intake, volume depletion, medication effects, neuropathy, deconditioning, infection physiology, and steroid-related physiology may all contribute.

Family recognizes that the patient is meaningfully different from baseline. Their later discharge concern is not generic anxiety; it is longitudinal patient knowledge.

### HD1 / 05/18/2026

Korvin presents to the ED as an undifferentiated medically complex patient with suspected urinary-source infection, poor oral intake, altered baseline mental status, weakness, near-fall context, renal/volume vulnerability, and high medication complexity. Sepsis-oriented stabilization is appropriate. Infection is a real or reasonable contributor, but the world should not treat it as the entire explanation.

Medication safety concerns begin immediately because chronic HFrEF/CAD/diabetes medications interact with AKI risk, poor intake, and borderline hemodynamics. Prednisone history is present but not yet reliably reconstructed. Functional decline exists but may be underweighted during early stabilization.

### HD2 / 05/19/2026

Some clinical features begin to improve after initial stabilization. The patient transitions from ED stabilization to inpatient management, and consultant involvement becomes clinically justified. Improvement creates the first risk of premature closure: a clinician may over-trust the initial infection frame and miss evolving renal, medication, steroid, and functional concerns.

Cardiology and nephrology concerns begin to diverge around medication safety versus long-term protective therapy. Endocrinology concern begins if chronic steroid exposure and unclear taper history are recognized as clinically relevant.

### HD3 / 05/20/2026

Functional and cognitive recovery become central. Korvin is clinically less acute but not back to baseline. Nursing, PT/OT, and family evidence may show weakness, cognitive fluctuation, mobility limitations, and difficulty with medication-management safety even while some acute medical features improve.

This day strengthens the distinction between medical stabilization and discharge readiness. Functional readiness is not established merely because infection-oriented treatment appears to be working.

### HD4 / 05/21/2026

Consultant disagreement and source-of-truth problems become explicit. Cardiology reasonably wants to preserve or restart long-term HFrEF/CAD therapy when safe. Nephrology reasonably prioritizes renal recovery, hypotension avoidance, and medication safety. Endocrinology reasonably worries that steroid exposure and taper uncertainty may influence persistent weakness, borderline symptoms, and discharge steroid planning. The primary team reasonably wants to avoid over-attributing the presentation to steroids after sepsis-oriented treatment produces improvement.

The prednisone history remains a source problem. Rheumatology history, verified medication reconciliation, pharmacy/refill history, family report, and patient recollection may not line up cleanly. The correct reasoning is reconstruction and risk interpretation, not "find the hidden adrenal insufficiency."

### HD5 / 05/22/2026

Disposition questions become dominant. The patient is improving enough that discharge planning is plausible, but safety remains uncertain. Functional reserve, cognition, medication plan coherence, family confidence, follow-up reliability, and steroid interpretation remain unresolved enough to matter.

Trap #5 becomes established here: a visible discharge-facing artifact or plan may look sufficient if trusted alone. The correct clinician must reconcile it against buried functional/cognitive evidence, consultant timing, medication complexity, steroid source hierarchy, and family concerns.

### HD6 / 05/23/2026

The world closes at 18:00 during discharge planning. Korvin is medically improved compared with presentation. Acute stabilization has occurred; infection/acute-illness burden is improved; renal/hemodynamic trajectory is improved enough to require medication reassessment rather than simple continuation of early holds; oral intake and alertness are improved compared with ED presentation; and multiple consultant and functional inputs now exist.

However, the patient remains operationally dangerous if the plan is handled superficially. Functional reserve remains uncertain, the medication restart/hold/taper strategy must be coherent, steroid history remains imperfect, family concern remains defensible, and a reassuring discharge plan may be incomplete if trusted alone.

### Discharge, +7, And +30 Anchors

The discharge anchor on 05/24/2026 is a post-world transition reference point. Discharge can be clinically defensible, but safety depends on synthesizing medication changes, functional status, family concerns, consultant recommendations, steroid plan, follow-up, and caregiver capacity.

The +7 anchor on 05/31/2026 supports early post-discharge reassessment. The correct frame is neither "missed adrenal insufficiency" nor "sepsis resolved, all done." It is reassessment of recovery, medication tolerance, renal/cardiac safety, steroid plan coherence, function, cognition, and transition support.

The +30 anchor on 06/23/2026 supports later patient-safety or readmission-risk reasoning without creating a new post-discharge event inside this World Spec candidate.

## 3. Friction Architecture

### Cardiology vs Nephrology: Medication Restart Timing

Cardiology's position is defensible because Korvin has established HFrEF and CAD with chronic protective therapy. Unnecessary withdrawal of guideline-directed therapy could increase the risk of decompensation, readmission, or loss of long-term cardiovascular protection.

Nephrology's position is defensible because Korvin has AKI-on-CKD risk, borderline hemodynamic concerns, poor intake, and renal-sensitive medications. Premature restart of all chronic therapies could worsen kidney function, hypotension, or medication safety.

The world should force timing and trend synthesis rather than "cardiology is right" or "nephrology is right."

### Family vs Primary Team: Discharge Readiness

Family's position is defensible because they know Korvin's baseline. They observed the pre-admission decline, medication-management mistakes, near-fall, cognitive slowing, and persistent deviation from baseline. They may reasonably worry that improved numbers or a better appearance do not equal safe home function.

The primary team's position is also defensible because the patient has improved compared with presentation. Infection and acute illness appear controlled enough for discharge planning, renal/hemodynamic concerns are improving, mental status and oral intake are better than on arrival, follow-up can be arranged, and prolonged hospitalization has its own risks.

The intended judgment problem is not whether the family is "right" or the team is "wrong." It is whether the discharge plan integrates functional evidence, medication changes, consultant recommendations, family concerns, follow-up, and home support.

### Endocrinology vs Primary Team: Steroid Interpretation And Risk

Endocrinology's position is defensible because Korvin has PMR, chronic prednisone exposure, recent taper history, inconsistent steroid sources, and persistent nonspecific symptoms that could overlap with inadequate adrenal reserve or unsafe steroid taper planning.

The primary team's position is defensible because sepsis-oriented treatment was appropriate and the patient improved. The team reasonably wants to avoid unnecessary steroid continuation or turning every residual symptom into adrenal insufficiency.

The steroid-record discrepancy is a trap, not a friction participant. The human friction is risk interpretation between Endocrinology and the Primary Team.

## 4. Trap Architecture

### Trap #1: Prednisone Source-of-Truth

The patient has PMR with chronic prednisone exposure, prior flares and taper attempts, and a recent taper because symptoms appeared controlled. Steroid status may be inconsistently represented across older rheumatology documentation, outpatient medication lists, admission medication reconciliation, pharmacy/refill history, family report, patient recollection, and copied-forward inpatient notes.

The clinically actionable question is not merely "is he taking prednisone?" The question is whether recent exposure was sufficient that adrenal suppression risk should influence acute management and discharge planning. Correct reasoning uses the prednisone-specific source-of-truth hierarchy and avoids making adrenal insufficiency the hidden answer.

### Trap #2: HF/AKI Medication Reconciliation And Time-Sensitive Consultant Logic

HFrEF/CAD/diabetes medications may be held or adjusted during acute illness, AKI risk, poor intake, and borderline hemodynamics. Early medication-hold recommendations may be appropriate at the time they are written but become incomplete later as the patient improves.

The failure modes are opposite but both plausible: restarting everything too early despite ongoing risk, or discharging without reviewing appropriate long-term protective therapy after improvement. Correct reasoning integrates nephrology notes, cardiology notes, trends, current clinical status, medication history, and discharge context.

### Trap #3: Buried Functional / Cognitive Status

Physician summary notes may describe Korvin as clinically improved or medically stable, while nursing, PT/OT, family communication, and bedside observations contain evidence of intermittent confusion, weakness, assistance needs, mobility limitations, or medication-management concern.

The key question is whether the clinician finds the important evidence. This trap is a hidden-evidence problem: clinically important information exists but may not be in the most obvious narrative summary.

### Trap #4: Sepsis Anchoring After Partial Improvement

The initial suspected urinary-source sepsis frame is reasonable. ED assessment, admission framing, early treatment response, and early labs or clinical features may appropriately support infection-oriented management.

The failure is assuming the initial diagnosis explains the entire hospitalization after partial improvement. Persistent weakness, borderline symptoms, medication changes, functional decline, steroid timeline questions, renal/hemodynamic concerns, and discharge safety require reassessment. Correct reasoning recognizes that infection may be real or reasonable initially while avoiding premature closure.

### Trap #5: Discharge Source-Hierarchy

By HD5-HD6, a visible discharge-facing artifact or plan may appear reassuring. It may summarize improvement, list follow-up, or imply medical stability. The danger is trusting that artifact alone.

This trap is distinct from Trap #3. Trap #3 asks whether the clinician found buried functional/cognitive evidence. Trap #5 asks whether, after seeing a visible and reassuring discharge source, the clinician recognizes it is incomplete and reconciles it against the rest of the world.

## 5. Task Architecture Mapping

The locked task architecture targets 6 task concepts across 4 approved workflows. This section explains how the world supports those future workflows. It does not create task prompts, expected outputs, final task specifications, task files, golden responses, or grader guidance.

| Rough task concept | Locked workflow | World support |
| --- | --- | --- |
| Discharge medication reconciliation / medication safety review | Discharge Medication Reconciliation | Supported by HF/AKI medication timing, prednisone source ambiguity, insulin/diabetes complexity, supportive medications, and early-hold vs later-restart reasoning. |
| Hospital discharge summary generation | Hospital Discharge Summary Generation | Supported by a multi-day course where early sepsis framing, consultant chronology, functional concerns, medication decisions, and unresolved follow-up issues must be summarized without copy-forward distortion. |
| Transition-of-care / discharge readiness plan | Discharge Planning Documentation | Supported by family concerns, PT/OT/nursing evidence, medication changes, follow-up needs, home support, and the medically-improved-but-operationally-dangerous discharge state. |
| Post-hospital follow-up assessment note | Discharge Planning Documentation | Supported by the +7 anchor and the need to distinguish expected recovery from unresolved problems in function, cognition, medication tolerance, renal/cardiac safety, and steroid plan coherence. |
| Consultant recommendation synthesis / care coordination note | Interdisciplinary Care Plan Development and Documentation | Supported by Cardiology vs Nephrology, Endocrinology vs Primary Team, and the hospitalist need to synthesize recommendations without blindly following the latest note or highest-ranked authority. |
| Readmission risk / patient safety review | Discharge Planning Documentation | Supported by the +30 anchor, discharge-source hierarchy, polypharmacy, functional decline, family concern, follow-up needs, and transition-of-care vulnerabilities. |

Authoritative workflows:

1. Discharge Medication Reconciliation.
2. Hospital Discharge Summary Generation.
3. Discharge Planning Documentation.
4. Interdisciplinary Care Plan Development and Documentation.

Transition-of-Care and readmission-risk reasoning remain embedded inside Discharge Planning Documentation rather than becoming standalone workflows. Discharge Planning Documentation carries the primary administrative deliverable through discharge planning, care coordination, transition support, and patient-safety reasoning.

## 6. World Summary

Korvin Merrow's world is difficult because he improves medically without becoming straightforwardly safe to discharge. The first diagnosis is reasonable, but the later challenge is deciding which information remains reliable after days of evolving clinical context, consultant recommendations, medication changes, functional observations, and family concerns.

The world tests source-of-truth reasoning, temporal synthesis, medication reconciliation, consultant disagreement management, and disposition-safety judgment. A strong clinician must avoid both premature sepsis closure and hidden-adrenal-insufficiency drift, reconstruct the steroid and medication timeline, integrate buried functional/cognitive evidence, and recognize that a reassuring discharge artifact may be incomplete.

## World Spec Consistency Review

### VERIFIED

Finding: World Spec v1 uses only locked architecture.

Evidence: identity, comorbidities, medications, providers, procedures, calendar anchors, frictions, traps, task workflows, baseline anchors, and daily course elements all come from locked or ratified source packages.

Impact: no locked decision is reopened.

Action required: physician review before any ratification or template population.

### VERIFIED

Finding: timeline consistency is preserved.

Evidence: decline begins 04/27/2026, admission is 05/18/2026, HD6 world close is 05/23/2026 at 18:00, discharge anchor is 05/24/2026, +7 is 05/31/2026, and +30 is 06/23/2026.

Impact: supports later temporal AutoQC gates.

Action required: do not add new dates without updating the canonical milestone framework.

### VERIFIED

Finding: medication consistency is preserved.

Evidence: the medication architecture contains the locked 20 baseline medications and explicitly excludes insulin lispro from baseline.

Impact: supports medication-reconciliation reasoning without creating medication schedules or outputs.

Action required: later medication-list construction must preserve this architecture unless Alexander reopens it.

### VERIFIED

Finding: comorbidity consistency is preserved.

Evidence: all 14 locked baseline conditions are represented and no new diagnosis is added.

Impact: preserves reviewer-target complexity without adding a new dominant arc.

Action required: none before review.

### VERIFIED

Finding: provider and procedural consistency are preserved.

Evidence: named high-authority providers, role-based minor contributors, shared Merrow surname, remote PCI, sleep study, and excluded procedures match locked packages.

Impact: source and authorship architecture remains stable for future file planning.

Action required: no additional provider naming or procedural history without explicit authorization.

### VERIFIED

Finding: friction continuity is preserved.

Evidence: Cardiology vs Nephrology, Family vs Primary Team, and Endocrinology vs Primary Team remain human-to-human disagreements with defensible positions.

Impact: frictions do not collapse into documentation conflicts or one-sided decisions.

Action required: preserve both sides during later task and file construction.

### VERIFIED

Finding: trap continuity is preserved.

Evidence: all five locked traps are stated and Trap #3 vs Trap #5 remains distinct.

Impact: future file construction can support multi-document synthesis without turning traps into single-document answers.

Action required: later file inventory must assign trap evidence carefully.

### VERIFIED

Finding: mixed physiology and discharge-safety design are preserved.

Evidence: infection, renal/volume vulnerability, HF/CAD medication reasoning, steroid uncertainty, neuropathy, deconditioning, cognitive vulnerability, family baseline knowledge, and functional reserve remain active contributors.

Impact: world remains a realistic hospital medicine case rather than a rare-disease puzzle.

Action required: maintain this balance in reviews.

### PLAUSIBLE

Finding: World Spec v1 can support all six future task concepts.

Evidence: each rough concept maps to a locked workflow and has clear world support.

Impact: task solvability is structurally plausible, but cannot be fully verified until task specs and file inventory are later authorized.

Action required: defer final task solvability proof until task specifications and file planning.

### NO ISSUE

Finding: no prohibited downstream artifacts are created.

Evidence: this candidate contains no file inventory rows, filenames, synthetic files, notes, labs, vitals, medication schedules, task prompts, expected outputs, goldens, grader guidance, AutoQC responses, reference files, templates, or submission artifacts.

Impact: construction boundaries remain intact.

Action required: stop before downstream phases.

### DISPUTED

Finding: none.

Evidence: no contradiction found with the locked source packages used for this candidate.

Impact: no redesign required before review.

Action required: physician and reviewer-style audit before lock.

## Final Status

World Spec v1

Status: CANDIDATE REVIEW
